Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Rhea-AI Summary
Rezolute (Nasdaq:RZLT) reported four presentations at the Endocrine Society’s annual ENDO meeting covering congenital and tumor hyperinsulinism (HI). Two posters detailed systematic natural history and health‑economic outcomes in congenital HI. Another poster showed Expanded Access Program tumor HI data, and an oral session reviewed Phase 3 sunRIZE congenital HI results.
In 9 tumor HI patients with refractory hypoglycemia, 75% on IV dextrose/TPN achieved complete discontinuation. Rezolute views these data, alongside natural history analyses, as supporting development and potential future launch of ersodetug for congenital and tumor HI.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Tumor HI EAP: 75% of 9 patients discontinued IV dextrose/TPN
- Phase 3 sunRIZE congenital HI results publicly reviewed at ENDO
- Natural history and claims-based studies quantify congenital HI burden
- Late-stage ersodetug programs in both congenital and tumor HI highlighted
Negative
- None.
News Market Reaction – RZLT
On the day this news was published, RZLT gained 4.81%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.2% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $23M to the company's valuation, bringing the market cap to $496.39M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 04 | ENDO preview news | Neutral | -1.5% | Announced upcoming four ENDO 2026 presentations for congenital and tumor HI. |
| Jun 02 | Phase 3 interim data | Positive | +10.8% | Reported positive interim Phase 3 upLIFT data in tumor hyperinsulinism. |
| May 12 | Earnings and update | Neutral | +0.9% | Q3 fiscal 2026 results with detailed ersodetug clinical and FDA updates. |
| May 11 | Investor conferences | Neutral | -1.3% | Announced participation in upcoming healthcare and investor conferences. |
| May 01 | sunRIZE data presentation | Positive | +3.1% | Presented expanded Phase 3 sunRIZE analyses showing glycemic improvements in HI. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows stronger, aligned upside reactions to positive Phase 3 data, while conference and schedule-related news have produced smaller or mixed moves, including occasional downside.
Over the past few months, Rezolute has repeatedly highlighted Phase 3 data for ersodetug in both congenital and tumor hyperinsulinism, alongside regular financial updates. Positive interim upLIFT data on Jun 02 coincided with a 10.8% gain, while expanded sunRIZE presentations on May 01 saw a 3.12% rise. In contrast, conference participation and ENDO preview announcements drew modest negative reactions. Today’s ENDO results presentation fits this pattern of ongoing late‑stage program visibility supported by earlier clinical signals.
Regulatory & Risk Context
Key Terms
congenital hyperinsulinism medical
hyperinsulinism medical
total parenteral nutrition medical
expanded access program regulatory
phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company’s Phase 3 sunRIZE study in congenital HI and a case series from its Expanded Access Program (EAP) in tumor HI
REDWOOD CITY, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today highlighted four data presentations delivered at the Annual Meeting of the Endocrine Society (ENDO).
Two poster presentations highlighted results from systematic analyses of the natural history and adverse neurologic and health-economic outcomes resulting from congenital HI, using a meta-analysis of the literature as well as a claims-based approach to quantifying congenital HI complications, respectively. This is an important step toward consolidating and quantifying the disease-impact and informing future health economics and outcomes research that will facilitate the development and potential future launch of the Company’s therapy, ersodetug, in this indication. A third poster presentation highlighted favorable outcomes from a case series report of 9 patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors (tumor HI), demonstrating that
In an oral presentation, Huseyin Demirbilek, M.D., Professor, Department of Pediatric Endocrinology, Hacettepe University Faculty of Medicine, Ankara, Turkey, and Principal Investigator of the Phase 3 sunRIZE study of ersodetug in congenital HI, reviewed previously reported sunRIZE results.
“We were pleased to have the opportunity to present at ENDO and to continue showcasing progress across our two late-stage programs in congenital and tumor HI,” said Brian Roberts, M.D., Chief Medical Officer of Rezolute. “Deeper analyses of the sunRIZE data demonstrate the meaningful therapeutic benefit of ersodetug, further supported by the positive outcomes observed in both our EAP and recently announced interim and preliminary Phase 3 upLIFT study observations in tumor HI patients. Additionally, the natural history outcomes studies further underscore the significant clinical outcomes impacts of this disease, and the urgent need for improved treatment options.”
Each of the Company’s full data presentations from ENDO can be found on the Publications and Presentations page of the Rezolute website here.
About Ersodetug
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from glucose absorption, gastrointestinal incretin hormones, and pancreatic insulin secretion, it has the potential to be universally effective at treating refractory hypoglycemia due to a congenital or any acquired form of HI, including tumor HI (insulinoma, NICTH) or hypoglycemia as a complication of a variety of bariatric or non-bariatric gastrointestinal surgeries.
About Rezolute, Inc.
Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the potential efficacy of ersodetug in treating hypoglycemia. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Rezolute Contacts:
Christen Baglaneas
508-272-6717
Carrie McKim
336-608-9706
